Inactive Instrument

Cellectar Biosciences Inc Stock price Nasdaq

Equities

US15117F3029

Pharmaceuticals

Sales 2024 * - Sales 2025 * 44.27M Capitalization 121M
Net income 2024 * -49M Net income 2025 * -22M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.74 x
P/E ratio 2024 *
-2.44 x
P/E ratio 2025 *
-6.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.48%
More Fundamentals * Assessed data
Dynamic Chart
Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer CI
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type MT
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient CI
Transcript : Cellectar Biosciences, Inc. - Special Call
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data CI
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting CI
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating MT
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia... Our Logo
Investors lower their expectations Our Logo
More news
Managers TitleAgeSince
Chief Executive Officer 65 15-06-14
Director of Finance/CFO 59 14-05-27
Chief Tech/Sci/R&D Officer - 23-02-14
Members of the board TitleAgeSince
Director/Board Member 73 17-04-06
Chairman 54 17-04-06
Director/Board Member 68 08-01-31
More insiders
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on to develop PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. It is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase 2 CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase 1 CLOVER-2 study.
More about the company
  1. Stock
  2. Equities
  3. Stock Cellectar Biosciences, Inc.
  4. Stock Cellectar Biosciences Inc - Nasdaq